Siemens Healthineers stock faces cautious 2027 outlook
Published on 11/05/2026 at 11:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSStrong quarter, cautious outlook
- Comparable fourth-quarter revenue growth reached 5.9 percent, led by Imaging.
- Diagnostics revenue declined on a comparable basis, while adjusted EBIT margin fell year over year.
- Fiscal 2027 guidance calls for 4.0 to 5.0 percent comparable revenue growth and adjusted basic earnings per share of 2.20 to 2.40 euros.
Siemens Healthineers reported a strong fourth quarter for fiscal 2026 but issued a more cautious outlook for the year ahead. In its press release published on Thursday, November 5, 2026, the medical technology group said comparable revenue rose 5.9 percent in the quarter ended September 30.
Siemens Healthineers stock traded at 43.75 euros on Lang & Schwarz at 11:07 CET on Thursday, November 5, 2026, 2.45 percent below the Xetra close of Wednesday, November 4. Investors can follow the real-time quote of Siemens Healthineers stock.
Imaging drives quarterly growth
Fourth-quarter revenue reached 6.784 billion euros, up 7.3 percent from the prior year. Adjusted basic earnings per share increased to 0.69 euros, while free cash flow reached 703 million euros. The equipment book-to-bill ratio of 1.15 pointed to continued order momentum.
Imaging was the strongest operating division, with comparable revenue growth of 10.0 percent and an adjusted EBIT margin of 21.9 percent. Precision Therapy delivered comparable growth of 4.8 percent and an adjusted EBIT margin of 13.8 percent.
Diagnostics remained the main drag on the quarter. Comparable revenue declined 4.2 percent, and the division posted an adjusted EBIT margin of 5.4 percent. At group level, the adjusted EBIT margin was 15.9 percent, below the prior-year figure of 17.4 percent, while adjusted EBIT fell 2.0 percent to 1.077 billion euros.
Guidance points to slower earnings
For fiscal 2027, Siemens Healthineers expects comparable revenue growth of 4.0 to 5.0 percent. Adjusted basic earnings per share are forecast at 2.20 to 2.40 euros, below the 2.42 euros reported for fiscal 2026. The company also proposed an unchanged dividend of 1.00 euro per share.
Chief Executive Bernd Montag said the group was entering a new phase with a different shareholder structure and greater corporate clarity. Management plans to sharpen the portfolio, strengthen the core businesses and begin the carve-out process for Diagnostics. The company also intends to evolve its brand and name to Healthineers.
Siemens Healthineers at a glance
- Company: Siemens Healthineers AG
- ISIN: DE000SHL1006
- Ticker: SHL.DE
- Lang & Schwarz price: 43.75 euros at 11:07 CET on November 5, 2026
- Change versus Xetra close: 2.45 percent lower than 44.85 euros on November 4, 2026
- Fiscal 2027 revenue outlook: 4.0 to 5.0 percent comparable growth
- Fiscal 2027 adjusted basic earnings per share outlook: 2.20 to 2.40 euros
Investors can follow the broader German market through current market reports.
